CARsgen Therapeutics Presents Updated Multiple Myeloma Cell Therapy Data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition

SHANGHAI, Dec. 6, 2020 /PRNewswire/ — CARsgen Therapeutics, a clinical-stage biopharmaceutical company, announced updated safety and efficacy results from its ongoing global clinical studies of CT053, an investigational chimeric antigen receptor (CAR) T-cell therapy for patients with…

About the Author

has written 20652 stories on this site.

Copyright © 2010-2019 strategicbusinessnews.com